All data are based on the daily closing price as of July 22, 2024
p

PharmaEngine

4162.TWO
2.80 USD
-0.08
-2.78%

Overview

Last close
2.80 usd
Market cap
402.43M usd
52 week high
3.74 usd
52 week low
2.48 usd
Target price
3.26 usd

Valuation

P/E
48.1675
Forward P/E
N/A
Price/Sales
18.1734
Price/Book Value
3.6116
Enterprise Value
322.20M usd
EV/Revenue
13.4666
EV/EBITDA
29.766

Key financials

Revenue TTM
23.25M usd
Gross Profit TTM
18.41M usd
EBITDA TTM
8.06M usd
Earnings per Share
0.06 usd
Dividend
0.05 usd
Total assets
127.22M usd
Net debt
N/A usd

About

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It offers ONIVYDE, a novel and stable encapsulated chemotherapy drug irinotecan for the treatment of metastatic pancreatic cancer and other indications of clinical development. The company is developing PEP07, a checkpoint kinase 1 inhibitor, which is in preclinical development stage for the treatment of hematologic cancers and solid cancers, such as acute myeloid leukemia and mantle cell lymphoma. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
  • Symbol
    4162.TWO
  • Exchange
    TWO
  • Isin
    TW0004162003
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Hong-Ren Wang Ph.D.
  • Headquarter
    Taipei
  • Web site
    https://www.pharmaengine.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top